A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2001
10/18/2001	CA2406484A1 Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents
10/18/2001	CA2406352A1 Peptide conjugates for drug delivery
10/18/2001	CA2406233A1 Compositions for drug delivery
10/18/2001	CA2406188A1 Methods for ansamitocin production
10/18/2001	CA2405895A1 Combination of organic compounds
10/18/2001	CA2405800A1 Novel secreted protein
10/18/2001	CA2405793A1 Combination of organic compounds
10/18/2001	CA2405591A1 Use of uric acid or precursors thereof as a treatment for cancer, aids and the like
10/18/2001	CA2405561A1 Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade
10/18/2001	CA2405554A1 Intracorporeal medicaments comprising halogenated xanthenes for high energy phototherapeutic treatment of disease
10/18/2001	CA2405471A1 Method for stabilising particle size distribution of a powdery active principle dispersed in a liquid and uses thereof
10/18/2001	CA2405452A1 Hair growth stimulant compositions
10/18/2001	CA2405425A1 Dermatological preparations containing thyronine derivatives and uses thereof
10/18/2001	CA2405419A1 Apomorphine derivatives and methods for their use
10/18/2001	CA2405413A1 Inhibition of cytokine generation
10/18/2001	CA2405411A1 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases
10/18/2001	CA2405360A1 Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity
10/18/2001	CA2405307A1 Application of substances acting as cascade inhibitors of the raf/mek/erk signaling cascade for the production of a drug against infections by dna and rna viruses
10/18/2001	CA2405306A1 Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade
10/18/2001	CA2405163A1 Soluble beta amyloid precursor protein secretion promoters
10/18/2001	CA2405152A1 Treatment of icu-associated hypocalcemia with vitamin d compounds
10/18/2001	CA2405151A1 Bile acid containing prodrugs with enhanced bioavailability
10/18/2001	CA2405142A1 A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
10/18/2001	CA2405089A1 Benzoamide piperidine containing compounds and related compounds
10/18/2001	CA2405070A1 Estrogen agonist/antagonist metabolites
10/18/2001	CA2405066A1 Percyquinnin, a process for its production and its use as a pharmaceutical
10/18/2001	CA2405012A1 Starch sub-types and lipid metabolism
10/18/2001	CA2405004A1 Therapeutically useful new salts of cck inhibitors, process for the preparation thereof and pharmaceutical preparations containing them
10/18/2001	CA2404994A1 Pyrazolo-triazine derivatives as ligands for gaba receptors
10/18/2001	CA2404915A1 Prophylactic and therapeutic use of oltipraz as an antifibrotic and anticirrhotic agent in the liver and pharmaceutical composition containing oltipraz
10/18/2001	CA2404889A1 Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
10/18/2001	CA2404864A1 Synergistic compositions containing choline base and succinic acid for insulin resistance and diabetes
10/18/2001	CA2404630A1 Cathepsin cysteine protease inhibitors
10/18/2001	CA2404273A1 Substituted lactams as inhibitors of a.beta. protein production
10/18/2001	CA2404087A1 Combination product comprising a non-steroidal antiandrogen and an egfr tyrosine kinase inhibitor
10/18/2001	CA2404044A1 Compounds and methods to increase plasma hdl cholesterol levels and improve hdl functionality
10/18/2001	CA2403365A1 Quinazoline compounds
10/18/2001	CA2403317A1 Mutant bank
10/18/2001	CA2403263A1 Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators
10/18/2001	CA2403144A1 Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
10/18/2001	CA2403140A1 Novel chromosomal vectors and uses thereof
10/18/2001	CA2403012A1 Chemical compounds
10/18/2001	CA2401836A1 Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies
10/18/2001	CA2400740A1 Treatment of skin damage using polyenylphosphatidylcholine
10/18/2001	CA2400386A1 Anthelmintic combinations
10/18/2001	CA2389691A1 A pre-incubation method for an assay of an inhibitor to an hcv rna-dependent rna polymerase
10/18/2001	CA2372352A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor
10/17/2001	EP1146337A1 Pgt and apoptosis
10/17/2001	EP1146122A2 Human G-protein chemokine receptor HDGNR10 (CCR5 receptor)
10/17/2001	EP1146055A2 Human G-protein chemokine receptor HDGNR10 (CCR5 receptor)
10/17/2001	EP1146051A2 Erythromycin A derivatives
10/17/2001	EP1146046A2 Pyropheophorbides and their use in photodynamic therapy
10/17/2001	EP1146044A1 CNS active cyclobuta-indole carboxamide derivatives, processes for their preparation and pharmaceutical compositions containing them
10/17/2001	EP1146043A1 Taxanes having an alkyl substituted side-chain and pharmaceutical compositions containing them
10/17/2001	EP1146041A1 Derivatives of heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane and their use as inhibitors of the recapture of serotonine and of noradrenaline
10/17/2001	EP1146035A1 Crystal polymorphism of aminoethylphenoxyacetic acid derivative
10/17/2001	EP1145721A2 Human G-protein chemokine receptor HDGNR10 (CCR5 receptor)
10/17/2001	EP1145717A2 Synergistic effect of a sulfonylurea and/or non-sulfonylurea K plus ATP channel blocker, and a phosphodiesterase 3 type inhibitor
10/17/2001	EP1145716A2 Therapeutic agent for the treatment of dermatitis
10/17/2001	EP1145715A2 Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
10/17/2001	EP1145714A1 Drugs
10/17/2001	EP1145713A1 Telomerase inhibitors
10/17/2001	EP1145711A1 Flash-melt oral dosage formulation
10/17/2001	EP1145710A1 Use of ascorbic acid derivatives for increasing epidermal ceramides synthesis
10/17/2001	EP1145709A1 Use of natural products to prepare cosmetic compositions
10/17/2001	EP1145706A1 Composition particularly for cosmetics comprising ascorbic acid in combination with an ascorbic acid derivative
10/17/2001	EP1145705A2 Composition, especially a cosmetic composition, containing a steroid and a 2-alkyl alkanol or ester thereof
10/17/2001	EP1144690A1 Antisense modulation of cellular inhibitor of apoptosis-2 expression
10/17/2001	EP1144682A2 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
10/17/2001	EP1144678A2 Susceptibility to psoriasis
10/17/2001	EP1144675A2 Pharmacokinetic-based drug design tool and method
10/17/2001	EP1144640A2 Nucleic acids and proteins from streptococcus pneumoniae
10/17/2001	EP1144634A2 Novel complex-forming proteins
10/17/2001	EP1144633A1 Polypeptide
10/17/2001	EP1144632A2 Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
10/17/2001	EP1144623A1 Method and medicament for inhibiting the expression of a defined gene
10/17/2001	EP1144614A2 33 human secreted proteins
10/17/2001	EP1144609A2 Chimeric antisense oligonucleotides and cell transfecting formulations thereof
10/17/2001	EP1144605A2 Dimethylarginine dimethylaminohydrolases
10/17/2001	EP1144592A2 Substrate for cell growth
10/17/2001	EP1144459A2 Cross-linked hyaluronic acids and medical uses thereof
10/17/2001	EP1144458A1 Substance for reduction of cholesterol as well as lipids content
10/17/2001	EP1144456A2 Method of isolating mucilaginous polysaccharides and uses thereof
10/17/2001	EP1144451A2 Method of modulating cell differentiation or neoplastic trnasformation by altering cadherin-11 expression or function
10/17/2001	EP1144441A2 Disintegrin homologs
10/17/2001	EP1144439A2 Hematopoietic regulatory factors and methods of use thereof
10/17/2001	EP1144432A1 Steroid derived antibiotics
10/17/2001	EP1144431A2 16-hydroxyestratrienes as selective estrogens
10/17/2001	EP1144428A1 Method for preparing an aza-macrolide with 4"(r)-nh2
10/17/2001	EP1144427A2 Macrolides with anti-inflammatory activity
10/17/2001	EP1144426A2 Benzylglycosylamides as inhibitors of smooth muscle cell proliferation
10/17/2001	EP1144425A1 Derivatives of monosaccharides as cell adhesion inhibitors
10/17/2001	EP1144423A1 Bis-terpyridine-platinum(ii) complexes
10/17/2001	EP1144421A1 Phosphinic pseudopeptides inhibitors of matrix metalloproteases
10/17/2001	EP1144420A1 Sulfated phosphatidylinositols, their preparation and use
10/17/2001	EP1144418A1 3,6-disubstituted penam sulfone derivatives as antibacterials
10/17/2001	EP1144415A2 Functionalized heterocycles as chemokine receptor modulators
10/17/2001	EP1144414A2 Compositions and methods relating to cyclic compounds that undergo nucleotide base pair-specific interactions with double-stranded nucleic acids
10/17/2001	EP1144413A1 2,5-diazabicyclo 2.2.1]heptane derivatives, their preparation and therapeutic uses
10/17/2001	EP1144412A1 Immunosuppressive effects of pteridine derivatives

1 ... 5989 5990 5991 5992 5993 5994 5995 5996 5997 5998 5999 6000 6001 6002 6003 6004 6005 6006 6007 6008 6009 ... 7860